Stephen (steve) Gracon
Vice President
Regulatory Consultant
NanoBio Corporation
United States of America
Biography
Steve Gracon served as NanoBio Corporation’s Vice President of Regulatory Affairs from 2008 through July 2015, and now serves as a consultant to the company. He has over 30 years of experience in the pharmaceutical industry, including roles at Parke-Davis, Pfizer, Amgen, and Baxter. Steve brings a diversity to NanoBio, having previously spent eight years in preclinical pathology and experimental toxicology, and more than a decade in clinical research, during which he lead the development of the tacrine (Cognex), the first drug approved for the treatment of Alzheimer’s disease. He then moved to regulatory affairs, gaining both U.S. and international regulatory experience.
Research Interest
Preclinical Pathology and Experimental Toxicology, and more than a decade in Clinical Research
